Yihong Sun1, Gaoqiang Xie2, Anushka Patel3, Shenshen Li4, Wei Zhao5, Xingzi Yang2, Tao Wu4, Min Li6, Xian Li4, Xin Du7, Rong Hu7, Yong Huo8, Dayi Hu9, Run Ling Gao10, Yangfeng Wu2,4,6. 1. China-Japan Friendship Hospital, Beijing, China. 2. Peking University Clinical Research Institute, Beijing, China. 3. The George Institute for Global Health, University of Sydney, Sydney, Australia. 4. The George Institute for Global Health at Peking University Health Science Center (PUHSC), Beijing, China. 5. Peking University Third Hospital, Beijing, China. 6. Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, China. 7. Beijing Anzhen Hospital, Capital Medical University, Beijing, China. 8. Peking University First Hospital, Beijing, China. 9. Peking University People's Hospital, Beijing, China. 10. Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Abstract
OBJECTIVE: The aim of this study was to investigate statin description on discharge and the benefit on the long-term outcomes in acute coronary syndromes (ACS) patients with very low baseline LDL-cholesterol (LDL-c). METHODS: This is a post-hoc analysis of 3374 ACS patients who were discharged alive and had baseline LDL-c levels below 70 mg/dL (1.8 mmol/L). The propensity score of using statin was estimated with a multivariable Logistic model including patient's demography, social economic status, cardiovascular risk factors, subtype of the diagnosis, and treatments received during hospitalization and current LDL-c level. The risk of major adverse cardiovascular events (MACEs) was compared between patients received and not-received statin with Cox-regression models adjusting for the propensity score plus other factors. A sensitivity analysis was done in propensity score matched patients. RESULTS: Compared with nonstatin group, the incidence of MACE at 12 months after discharge was lower in the statin group (11.1% vs 5.8%; P < 0.001). The propensity score plus other factors-adjusted hazard ratios for MACEs was significant (0.58; 95% CI: 0.39, 0.87). The effect showed a significant dose-response relationship (P for trend = 0.02). The results in analyses with propensity-score matched participants were in consistent with above findings. Analyses on total mortality in 12 months showed similar results. CONCLUSIONS: Among ACS survivors with a very low baseline LDL-c, low to moderate intensity statin therapy was associated significantly with lower risk of MACEs and total mortality at 12 months. The results suggested that ACS survivors should take statin regardless of the baseline of LDL-c.
OBJECTIVE: The aim of this study was to investigate statin description on discharge and the benefit on the long-term outcomes in acute coronary syndromes (ACS) patients with very low baseline LDL-cholesterol (LDL-c). METHODS: This is a post-hoc analysis of 3374 ACS patients who were discharged alive and had baseline LDL-c levels below 70 mg/dL (1.8 mmol/L). The propensity score of using statin was estimated with a multivariable Logistic model including patient's demography, social economic status, cardiovascular risk factors, subtype of the diagnosis, and treatments received during hospitalization and current LDL-c level. The risk of major adverse cardiovascular events (MACEs) was compared between patients received and not-received statin with Cox-regression models adjusting for the propensity score plus other factors. A sensitivity analysis was done in propensity score matched patients. RESULTS: Compared with nonstatin group, the incidence of MACE at 12 months after discharge was lower in the statin group (11.1% vs 5.8%; P < 0.001). The propensity score plus other factors-adjusted hazard ratios for MACEs was significant (0.58; 95% CI: 0.39, 0.87). The effect showed a significant dose-response relationship (P for trend = 0.02). The results in analyses with propensity-score matched participants were in consistent with above findings. Analyses on total mortality in 12 months showed similar results. CONCLUSIONS: Among ACS survivors with a very low baseline LDL-c, low to moderate intensity statin therapy was associated significantly with lower risk of MACEs and total mortality at 12 months. The results suggested that ACS survivors should take statin regardless of the baseline of LDL-c.
Authors: Emily C O'Brien; Jingjing Wu; Phillip J Schulte; Alexander Christian; Warren Laskey; Deepak L Bhatt; Eric D Peterson; Adrian F Hernandez; Gregg C Fonarow Journal: Am Heart J Date: 2015-12-17 Impact factor: 4.749
Authors: Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen Journal: N Engl J Med Date: 2017-03-17 Impact factor: 91.245
Authors: Scott M Grundy; James I Cleeman; C Noel Bairey Merz; H Bryan Brewer; Luther T Clark; Donald B Hunninghake; Richard C Pasternak; Sidney C Smith; Neil J Stone Journal: Circulation Date: 2004-07-13 Impact factor: 29.690
Authors: Alf I Larsen; Matthew I Tomey; Roxana Mehran; Dennis W T Nilsen; Ajay J Kirtane; Bernhard Witzenbichler; Giulio Guagliumi; Sorin J Brener; Philippe Généreux; Ran Kornowski; Dariusz Dudek; Bernard J Gersh; Gregg W Stone Journal: Am J Cardiol Date: 2014-01-31 Impact factor: 2.778
Authors: Roberto R Giraldez; Robert P Giugliano; Satishkumar Mohanavelu; Sabina A Murphy; Carolyn H McCabe; Christopher P Cannon; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2008-09-09 Impact factor: 24.094